New Studies By Cognition Therapeutics Researchers Reveal COGRX’s Memory Restoration Benefits

New Studies By Cognition Therapeutics Researchers Reveal COGRX’s Memory Restoration Benefits
memoryCognition Therapeutics Inc. announced the discovery of a new drug target in the brain that plays a role in the development of Alzheimer's disease, and their investigation of new drug candidates to reverse the memory loss associated with Alzheimer's. The two studies were entitled "Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers I: Abeta oligomers binding to specific neuronal receptors is displaced by drug candidates that improve cognitive deficits" and "Alzheimer's therapeutics targeting Amyloid beta 1-42 oligomers II: sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity." Both were published in the PlosOne journal. In the first study, the authors report the finding of a new receptor associated with Alzheimer's disease — sigma-2/PGRMC1 (progesterone receptor membrane component 1) — by mediating the attachment of Amyloid beta oligomers to neurons, disrupting their normal function and leading to memory loss. They developed further functional studies and generated novel therapeutic antagonists against the receptor that were able to block the toxicity effects of Amyloid beta both in vitro and i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *